Novel strategies for targeting innate immune responses to influenza

Mucosal Immunology

Volumn 9, Issue 5, 2016, Pages 1173-1182

  Shirey, K A ^a   Lai, W ^a   Patel, M C ^a,b   Pletneva, L M ^b   Pang, C ^c   Kurt Jones, E ^c   Lipsky, M ^a   Roger, T ^d   Calandra, T ^d   Tracey, K J ^e   Al Abed, Y ^e   Bowie, A G ^f   Fasano, A ^g   Dinarello, C A ^h   Gusovsky, F ⁱ   Blanco, J C G ^b   Vogel, S N ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Sigmovir Biosystems Inc   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^f TRINITY COLLEGE DUBLIN   (Ireland)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h UNIVERSITY OF COLORADO   (United States)

ⁱ EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ERITORAN; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 1BETA; LARAZOTIDE; OSELTAMIVIR; P 5779; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; UNCLASSIFIED DRUG; DISACCHARIDE; HMGB1 PROTEIN, MOUSE; IL1RAP PROTEIN, MOUSE; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; SUGAR PHOSPHATE; TLR2 PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 2;

ACUTE LUNG INJURY; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; IN VITRO STUDY; INFLUENZA; INNATE IMMUNITY; LETHALITY; LUNG EDEMA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; YOUNG ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; KNOCKOUT MOUSE; LUNG; MOLECULARLY TARGETED THERAPY; MORTALITY; MOUSE; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PATHOGENICITY; PATHOLOGY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; VIROLOGY;

ACUTE LUNG INJURY; ANIMALS; ANTIVIRAL AGENTS; DISACCHARIDES; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION; HMGB1 PROTEIN; IMMUNITY, INNATE; IMMUNOGLOBULIN G; INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN; LUNG; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; SIGNAL TRANSDUCTION; SUGAR PHOSPHATES; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 84982286528     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2015.141     Document Type: Article

References (59)

1. Belongia, E.A., Sundaram, M.E., McClure, D.L., Meece, J.K., Ferdinands, J., & VanWormer, J. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. Vaccine 33, 246-251 (2015
2. Flannery, B., et al. Early estimates of season influenza vaccine effectiveness-United States, January 2015. Morb. Mortal. Wkly. Rep. 64, 10-15 (2015
3. Pebody, R.G., et al. Low effectiveness of season influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 mid-season results. Eurosurveil. 20, pii 21025; doi: http: //dx.doi.org/10.2807/1560-7917.ES2015.20.5.21025 (2015
4. McLean, H.Q., et al. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by and virus type. J. Infect. Dis. 211, 1529-1540 (2015
5. Leung, Y.H., et al. Highly pathogenic avian influenza A H5N1 and pandemic H1N1 virus infections have different phenotypes in Toll-like receptor 3 knockout mice. J. Gen. Virol. 95, 1870-1879 (2014
6. Diebold, S.S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. Innate antiviral responses by means of TLR7-mediated recognition of singlestranded RNA. Science 303, 1529-1531 (2004
7. Heil, F., et al. Species-specific recognition of single-stranded RNA via tolllike receptor 7 and 8. Science 303, 1526-1529 (2004
8. Kawai, T., & Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat.Immunol. 11, 373-384 (2010
9. Seo, S.U., et al. MyD88 signaling is indispensable for primary influenza A virus infection but dispensable for secondary infection. J. Virol. 84, 12713-12722 (2010
10. Iwasaki, A., & Pillai, P.S. Innate immunity to influenza virus infection. Nat. Rev. Immunol. 14, 315-328 (2014
11. Tsai, S.Y., et al. DAMP molecule S100A9 acts as a molecular pattern to enhance inflammation during influenza A virus infection: role of DDX21-TRIF-TLR4-MyD88 pathway. PLoS Pathog. 10, e1003848 (2014
12. Teijaro, J.R., Walsh, K.B., Rice, S., Rosen, H., & Oldstone, M.B. Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection. Proc. Natl. Acad. Sci. USA 111, 3799-3804 (2014
13. Pauligk, C., Nain, M., Reiling, N., Gemsa, D., & Kaufmann, A. CD14 is required for influenza A virus-induced cytokine and chemokine production. Immunobiology 209, 3-10 (2004
14. Imai, Y., et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133, 235-249 (2008
15. Lien, E., et al. A novel synthetic acyclic lipid A-like agonist activates cells via the lipopolysaccharide/toll-like receptor 4 signaling pathway. J. Biol. Chem. 276, 1873-1880 (2001
16. Shirey, K.A., et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature 497, 498-502 (2013
17. Nhu, Q.M., et al. Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivo. Mucosal Immunol. 3, 29-39 (2010
18. Ye, J., et al. Variations in the hemagglutinin of the 2009 H1N1 pandemic virus: potential for strains with altered virulence phenotype?. PLoS Pathog. 6, e1001145 (2010
19. Kim, H.M., et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130, 906-917 (2007
20. Roger, T., et al. Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc. Natl. Acad. Sci. USA 106, 2348-2352 (2009
21. Kawai, T., Adachi, O., Ogawa, T., Takeda, K., & Akira, S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11, 115-122 (1999
22. Lysakova-Devine, T., et al. Viral inhibitory peptide of TLR4, a peptide derived from vaccinia protein A46, specifically inhibits TLR4 by directly targeting MyD88 adaptor-like and TRIF-related adaptor molecule. J. Immunol. 185, 4261-4271 (2010
23. Meng, G., et al. Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J. Clin. Invest. 113, 1473-1481 (2004
24. Wang, H., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248-251 (1999
25. Alleva, L.M., Budd, A.C., & Clark, I.A. Systemic release of high mobility group box 1 protein during severe murine influenza. J. Immunol. 181, 1454-1459 (2008
26. Yang, H., Antoine, D.J., Andersson, U., & Tracey, K.J. The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J. Leukoc. Biol. 93, 865-873 (2013
27. Yang, H., et al. MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. J. Exp. Med. 212, 5-14 (2015
28. Tripathi, A., et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc. Natl. Acad. Sci. USA 106, 16799-16804 (2009
29. Goldblum, S.E., et al. The active Zot domain (aa 288-293) increases ZO-1 and myosin 1C serine/threonine phosphorylation, alters interaction between ZO-1 and its binding partners, and induces tight junction disassembly through proteinase activated receptor. FASEB J. 25, 144-158 (2011
30. Rallabhandi, P., et al. Analysis of proteinase-activated receptor 2 and TLR4 signal transduction: a novel paradigm for receptor cooperativity. J. Biol. Chem. 283, 24314-24325 (2008
31. Paterson, B.M., Lammers, K.M., Arrieta, M.C., Fasano, A., & Meddling, J.B. The safety, tolerance, pharmacokinetic and pharmacodynamics effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment. Pharmacol. Ther. 26, 757-766 (2007
32. Rittirsch, D., et al. Zonulin as prehaptoglobin2 regulates lung permeability and activates the complement system. Am. J. Physiol. Lung Cell. Mol. Physiol. 304, L863-L872 (2013
33. Dinarello, C.A., Simon, A., & Van Der Meer, J.W. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 11, 633-652 (2012
34. Khazeni, N., Bravata, D.M., Holty, J.E., Uyeki, T.M., Stave, C.D., & Gould, M.K. Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. Ann. Intern. Med. 151, 464-473 (2009
35. Freund, B., Gravenstein, S., Elliott, M., & Miller, I. Zanamivir: a review of clinical safety. Drug Saf. 21, 267-281 (1999
36. Zheng, B.J., et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc. Natl. Acad. Sci. USA 105, 8091-8096 (2008
37. Kaneko, K., Ueda, R., Nemoto, H., Iijima, H., & Yoshimura, T. Disposition of a synthetic analog of lipid A (E5564) in rats. Xenobiotica 33, 323-339 (2003
38. Kalil, A.C., et al. Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis. Shock 36, 327-331 (2011
39. Mullarkey, M., et al. Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther. 304, 1093-1102 (2003
40. Piao, W., et al. A decoy peptide that disrupts TIRAP recruitment to TLRs is protective in a murine model of influenza. Cell Rep. 11, 1941-1952 (2015
41. Means, T.K., Lien, E., Yoshimura, A., Wang, S., Golenbock, D.T., & Fenton, M.J. The CD14 ligands lipoarabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors. J. Immunol. 163, 6748-6755 (1999
42. Lee, H.K., Dunzendorfer, S., Soldau, K., & Tobias, P.S. Double-stranded RNA mediated TLR3 activation is enhanced by CD14. Immunity 24, 153-163 (2006
43. Baumann, C.L., et al. CD14 is a coreceptor of Toll-like receptors 7 and 9. J. Exp. Med. 207, 2689-2701 (2010
44. Shirey, K.A., et al. The anti-tumor agent, 5, 6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo. J. Leukoc. Biol. 89, 351-357 (2011
45. Kadl, A., et al. Oxidized phospholipid-induced inflammation is mediated by Toll-like receptor 2. Free Radic. Biol. Med. 51, 1903-1909 (2011
46. Rodrigue-Gervais, I.G., et al. Cellular inhibitor of apoptosis protein cIAP2 protects against pulmonary tissue necrosis during influenza virus infection to promote host survival. Cell Host Microbe 15, 23-35 (2014
47. Sridharan, H., & Upton, J.W. Programmed necrosis in microbial pathogenesis. Trends Microbiol. 22, 199-207 (2014
48. Qing, D.Y., et al. Red blood cells induce necroptosis of lung endothelial cells and increase susceptibility to lung inflammation. Am. J. Respir. Crit. Care Med. 190, 1243-1254 (2014
49. Zhang, S., et al. Small intestinal injury in mice infected with respiratory influenza A virus: evidence for virus induced gastroenteritis. Biotechnol. Lett. 37, 1585-1592 (2015
50. Ichinohe, T., et al. Microbiota regulates immune defense against respiratory tract influenza Avirus infection. Proc.Natl. Acad. Sci.USA108, 5354-5359 (2011
51. Sodhi, C.P, et al. Intestinal epithelial TLR-4 activation is required for development of acute lung injury after trauma/hemorrhagic shock via the release of HMGB1 from the gut. J. Immunol. 194, 4931-4939 (2015
52. Cohen, I., et al. Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc. Natl. Acad. Sci. USA 107, 2574-2579 (2010
53. Kim, B., et al. The interleukin-1alpha precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines. Front. Immunol. 4, 391 (2013
54. Swain, S.L., Dutton, R.W., & Woodlan, D.L. T cell responses to influenza virus infection: effector and memory cells. Viral Immunol. 17, 197-209 (2004
55. McIntire, F.C., Sievert, H.W., Barlow, G.H., Finley, R.A., & Lee, Y. Chemical, physical, biological properties of a lipopolysaccharide from Escherichia coli K-235. Biochemistry 6, 2363-2376 (1967
56. Teijaro, J.R., et al. Costimulation modulation uncouples protection from immunopathology in memory Tcell response to influenza virus. J. Immunol. 82, 6834-6843 (2009
57. Blanco, J.C., et al. Receptor characterization and susceptibility of cotton rats to avian and 2009 pandemic influenza virus strains. J. Virol. 87, 2036-2045 (2013
58. Tate, M.D., Brooks, A.G., & Reading, P.C. The role of neutrophils in the upper and lower respiratory tract during influenza virus infection in mice. Respiratory Res. 9, 57-70 (2008
59. Feng, C., et al. Neuraminidase reprograms lung tissue and potentiates lipolysaccharide-induced acute lung injury in mice. J. Immunol. 191, 4828-4837 (2013